Rough Draft Atlanta on MSN1d
Researchers expect FDA to approve a twice-yearly shot that reduces risk of HIV infection by 96%Roughly 61,000 Georgians live with HIV, the sexually transmitted virus (STI) that can lead to AIDS, and Atlanta ranks in the ...
Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
Irish Independent on MSN1d
Gilead gives its blessing to Poolbeg Pharma’s Hookpia merger dealUS biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...
(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...
A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...
Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...
The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...
China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...
GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...
Uganda is registering around 38,000 new infections despite the deployment of different interventions such as condoms and oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback